Regulating the Activity of Dopaminergic Cell Transplants for Parkinson's Disease via the Hypoxia Inducible Factor Pathway (360G-Wellcome-228306_Z_23_Z)
Parkinson’s disease is a devastating neurodegenerative disease defined by its characteristic motor symptoms attributable to the selective loss of dopaminergic neurons within the ventral midbrain1. A promising approach to alleviate such symptoms involves the intracerebral transplantation of dopaminergic neurons generated from human embryonic stem cells (hESCs)2,3. However, in preclinical studies, these cells have shown variable survival and function4. Establishing a means to reduce this variability is vital to ensure consistent clinical outcomes across all patients. Manipulation of the Hypoxia- Inducible Factor (HIF) pathway, a well-conserved signalling pathway that allows cells to sense and adapt to hypoxia, is known to alter the physiology of several subtypes of dopaminergic cells5. Whether such manipulation produces comparable effects in hESC-derived dopaminergic neurons remains unknown but could represent a way to achieve clinical consistency. To address this issue, we will explore how pharmacological and genetic modulation of the HIF pathway impacts the physiology of hESC-derived dopaminergic neurons in cell culture and following transplantation into a well-established neurotoxic rodent model of Parkinson’s. It is hoped that such work will help to establish hESC-derived dopaminergic neuron transplantation as a robust therapeutic strategy, which will significantly improve the future of Parkinson's treatment.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.